Abstract
Blockage of transcription has been shown to induce the tumor suppressor p53 in human cells. We here show that RNA synthesis inhibitors blocking the phosphorylation of the carboxyl terminal domain (CTD) of RNA polymerase II, such as DRB and H7, induced rapid nuclear accumulation of p53 proteins that were not phosphorylated at ser15 or acetylated at lys382. In contrast, agents that inhibit the elongation phase of transcription, such as UV light, camptothecin or actinomycin D, induced the accumulation of nuclear p53 proteins that were modified at both of these sites. Furthermore, using a panel of DNA repair-deficient cells we show that persistent DNA lesions in the transcribed strand of active genes are responsible for the induction of the ser15 and lys382 modifications following UV-irradiation. We conclude that inhibition of transcription is sufficient for the accumulation of p53 in the nucleus regardless of whether the ser15 site of p53 is phosphorylated or not. Importantly, blockage of the elongation phase of transcription triggers a distinct signaling pathway leading to p53 modifications on ser15 and lys382. We propose that the elongating RNA polymerase complex may act as a sensor of DNA damage and as an integrator of cellular stress signals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
An WG, Chuman Y, Fojo T, Blagosklonny MV . 1998 Exp. Cell. Res. 244: 54–60
Ashcroft M, Taya Y, Vousden KH . 2000 Mol. Cell. Biol. 20: 3224–3233
Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y . 1998 Science 281: 1674–1677
Bender K, Blattner C, Knebel A, lordanov M, Herrlich P, Rahmsdorf HJ . 1997 J. Photochem. Photobiol. B: Biol. 37: 1–17
Blattner C, Sparks A, Lane D . 1999a Mol. Cell. Biol. 19: 3704–3713
Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P . 1999b Oncogene 18: 1723–1732
Boyd SD, Tsai KY, Jacks T . 2000 Nat. Cell Biol. 2: 563–568
Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD . 1998 Science 281: 1677–1679
Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD . 1999 Proc. Natl. Acad. Sci. USA 96: 13777–13782
Chen AY, Liu LF . 1994 Annu. Rev. Pharmacol. Toxicol. 34: 191–218
Christians FC, Hanawalt PC . 1994 Mutat. Res. 323: 179–187
Dubois MF, Nguyen VT, Bellier S, Bensaude O . 1994 J. Biol. Chem. 269: 13331–13336
Dumaz N, Meek DW . 1999 EMBO J. 18: 7002–7010
Fiscella M, Ullrich S, Zambrano N, Shields M, Lin D, Less-Miller S, Anderson C, Mercer W, Apella E . 1995 Oncogene 8: 1519–1528
Friedberg E, Walker G, Siede W . 1995 DNA Repair and Mutagenesis ASM Press: Washington, D.C
Geyer RK, Yu ZK, Maki CG . 2000 Nat. Cell Biol. 2: 569–573
Groulx I, Bonicalzi ME, Lee S . 2000 J. Biol. Chem. 275: 8991–9000
Gu W, Roeder RG . 1997 Cell 90: 595–606
Hirose Y, Manley JL . 2000 Genes Dev. 14: 1415–1429
Hupp T, Sparks A, Lane D . 1995 Cell 83: 237–245
Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP . 2001 EMBO J. 20: 1331–1340
Koumenis C, Giaccia A . 1997 Mol. Cell. Biol. 17: 7306–7316
Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN . 1998 J. Biol. Chem. 273: 33048–33053
Le Page F, Kwoh EE, Avrutskaya A, Gentil A, Leadon SA, Sarasin A, Cooper PK . 2000 Cell 101: 159–171
Ljungman M . 2000 Neoplasia 2: 208–225
Ljungman M, Hanawalt PC . 1996 Carcinogenesis 17: 31–35
Ljungman M, Zhang F . 1996 Oncogene 13: 823–831
Ljungman M, Zhang FF, Chen F, Rainbow AJ, McKay BC . 1999 Oncogene 18: 583–592
Lu X, Burbidge SA, Griffin S, Smith HM . 1996 Oncogene 13: 413–418
Marshall NF, Peng JM, Xie Z, Price DH . 1996 J. Biol. Chem. 271: 27176–27183
McKay B, Chen F, Clarke S, Wiggin H, Harley L, Ljungman M . 2001 Mutat. Res. 485: 93–105
McKay B, Ljungman M . 1999 Neoplasia 1: 276–284
McKay BC, Chen F, Perumalswami CR, Zhang FF, Ljungman M . 2000 Mol. Biol. Cell 11: 2543–2551
McKay BC, Ljungman M, Rainbow AJ . 1998 Oncogene 17: 545–555
Mello JA, Lippard SJ, Essigmann JM . 1995 Biochemistry 34: 14783–14791
Mellon I, Spivak G, Hanawalt PC . 1987 Cell 51: 241–249
Neish AS, Anderson SF, Schlegel BP, Wei WJ, Parvin JD . 1998 Nucleic Acids Res 26: 847–853
Perry M, Piette J, Zawadzki J, Harvey D, Levine A . 1993 Proc. Natl. Acad. Sci. USA 90: 11623–11627
Poele RHT, Okorokov AL, Joel SP . 1999 Oncogene 18: 5765–5772
Price DH . 2000 Mol. Cell. Biol. 20: 2629–2634
Proudfoot N . 2000 Trends Biochem. Sci. 25: 290–293
Reinke V, Lozano G . 1997 Radiat. Res. 148: 115–122
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E . 1998 Genes Dev. 12: 2831–2841
Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW, Appella E . 2000 J. Biol. Chem. 275: 9278–9283
Sauerbier W, Hercules K . 1978 Annu. Rev. Genet. 12: 329–363
She QB, Chen N, Dong Z . 2000 J. Biol. Chem. 275: 20444–20449
Shieh SY, Ikeda M, Taya Y, Prives C . 1997 Cell 91: 325–334
Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB . 1997 Genes Dev. 11: 3471–3481
Sobell H . 1985 Proc. Natl. Acad. Sci. USA 82: 5328–5331
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT . 1999 Genes Dev. 13: 152–157
Unger T, Juven-Gershon T, Moallem E, Berger M, Sionov RV, Lozano G, Oren M, Haupt Y . 1999a EMBO J. 18: 1805–1814
Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, Haupt Y . 1999b Oncogene 18: 3205–3212
Venema J, Vanhoffen A, Karcagi V, Natarajan AT, Vanzeeland AA, Mullenders LHF . 1991 Mol. Cell. Biol. 11: 4128–4134
Wang JA, Fan S, Yuan RQ, Ma YX, Meng Q, Goldberg ID, Rosen EM . 1999 Int. J. Radiat. Biol. 75: 301–316
Yamaizumi M, Sugano T . 1994 Oncogene 9: 2775–2784
Yuan ZM, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y, Kufe D . 1999 J. Biol. Chem. 274: 1883–1886
Acknowledgements
We thank Bruce McKay for valuable input and Sara Ljungman for critically reading this manuscript. This work was supported by a grant from the National Institute of Health (CA82376-01).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ljungman, M., O'Hagan, H. & Paulsen, M. Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20, 5964–5971 (2001). https://doi.org/10.1038/sj.onc.1204734
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204734
Keywords
This article is cited by
-
Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine
BMC Molecular and Cell Biology (2019)
-
Human p53 interacts with the elongating RNAPII complex and is required for the release of actinomycin D induced transcription blockage
Scientific Reports (2017)
-
DNA damage and the balance between survival and death in cancer biology
Nature Reviews Cancer (2016)
-
The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status
BMC Cancer (2009)
-
Induction of apoptosis and cellular senescence in mice lacking transcription elongation factor, Elongin A
Cell Death & Differentiation (2007)